3,267 results match your criteria progression rcc


[Eosinophilic solid and cystic renal cell carcinoma: a clinicopathological analysis of four cases].

Zhonghua Zhong Liu Za Zhi 2021 Sep;43(9):955-958

Department of Pathology, the Second Hospital of Longyan, Longyan 364000, China.

To study the clinicopathological characteristics and prognosis of eosinophilic solid and cystic renal cell carcinoma (ESC RCC). The clinical pathologic data of 4 cases of ESC RCC diagnosed and treated from 2017 to 2019 at the Second Hospital of Longyan City, the Second Affiliated Hospital of Fujian Medical University, and the Zhangzhou Municipal Hospital were collected. The expression of different antibodies was detected by immunohistochemistry, and the diagnosis and differentiate diagnosis were investigated. Read More

View Article and Full-Text PDF
September 2021

Quantitative global proteome and phosphorylome analyses reveal potential biomarkers in kidney cancer.

Oncol Rep 2021 Nov 16;46(5). Epub 2021 Sep 16.

Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China.

Currently, high‑throughput quantitative proteomic and transcriptomic approaches have been widely used for exploring the molecular mechanisms and acquiring biomarkers for cancers. Our study aimed to illuminate the multi-dimensional molecular mechanisms underlying renal cell carcinoma (RCC) via investigating the quantitative global proteome and the profile of phosphorylation. A total of 5,428 proteins and 8,632 phosphorylation sites were quantified in RCC tissues, with 709 proteins and 649 phosphorylation sites found to be altered in expression compared with the matched adjacent non‑tumor tissues. Read More

View Article and Full-Text PDF
November 2021

Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions.

Front Oncol 2021 30;11:707214. Epub 2021 Aug 30.

Department of Oncology, Goulburn Valley Health, Shepparton, VIC, Australia.

The incidence of renal cell carcinoma (RCC) is rising and metastatic RCC carries a very poor prognosis. The treatment paradigm for metastatic RCC has shifted dramatically in the last decade with multi-targeted tyrosine kinase inhibitors (TKI) previously used as first-line treatment but its utility is limited by short-lived efficacy and rapid disease progression. The dysregulation of immune cells in the tumour microenvironment contributes to unregulated growth of RCC. Read More

View Article and Full-Text PDF

Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.

BMC Cancer 2021 Sep 14;21(1):1021. Epub 2021 Sep 14.

Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.

Background: Clinical effectiveness and safety data of pazopanib in patients with advanced or mRCC in real-world setting from Asia Pacific, North Africa, and Middle East countries are lacking.

Methods: PARACHUTE is a phase IV, prospective, non-interventional, observational study. Primary endpoint was the proportion of patients remaining progression free at 12 months. Read More

View Article and Full-Text PDF
September 2021

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.

J Immunother Cancer 2021 Sep;9(9)

Department of Medicine, Center for Prostate & Urologic Cancers, Duke Cancer Institute, Durham, North Carolina, USA

The combination of ipilimumab plus nivolumab (I+N) has greatly improved outcomes in patients with intermediate or poor-risk untreated metastatic renal cell carcinoma (mRCC). However, little is known about the outcomes of patients with brain metastasis (BrM) treated with I+N. A search was performed to retrospectively identify all patients with mRCC treated with I+N in the Duke Cancer Institute and the Cleveland Clinic Taussig Cancer Center, followed by a chart review. Read More

View Article and Full-Text PDF
September 2021

Circular RNA FOXP1 Induced by ZNF263 Upregulates U2AF2 Expression to Accelerate Renal Cell Carcinoma Tumorigenesis and Warburg Effect through Sponging miR-423-5p.

J Immunol Res 2021 3;2021:8050993. Epub 2021 Sep 3.

Department of Urology, Huai'an Second People's Hospital and the Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China.

Renal cell carcinoma (RCC), as one of the most common malignant tumors in the urinary system, is featured with high morbidity and mortality. Although the improvement of clinical intervention, such as surgery technology, chemotherapy, and radiotherapy, has been made, the outcomes of RCC patients are still poor. Novel targets for RCC treatment are urgently needed. Read More

View Article and Full-Text PDF
September 2021

Xp11.2 Translocation Renal Cell Carcinoma: Clinical Characteristics and Potential Prognostic Predictors.

Dis Markers 2021 1;2021:5647933. Epub 2021 Sep 1.

Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China 100730.

Background: Xp11.2 translocation renal cell carcinoma, a rare malignancy, has a higher prevalence in children than in adults. It is relatively indolent in children but manifests with an aggressive course in adults. Read More

View Article and Full-Text PDF
September 2021

The Role of C-Reactive Protein in Kidney, Bladder, and Prostate Cancers.

Front Immunol 2021 27;12:721989. Epub 2021 Aug 27.

Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, United States.

C-Reactive Protein (CRP) is associated with diverse outcomes in patients with, or suspected to have, genitourinary malignancies. CRP levels have been shown to be associated with the probability of a prostate cancer diagnosis in patients with elevated PSA, the probability of biochemical recurrence following definitive treatment for localized prostate cancer, and decreased overall survival for patients with advanced disease. In patients with bladder and kidney cancers, CRP levels have been associated with disease progression, stage, and cancer-specific survival. Read More

View Article and Full-Text PDF

Cyclovirobuxine inhibits the progression of clear cell renal cell carcinoma by suppressing the IGFBP3-AKT/STAT3/MAPK-Snail signalling pathway.

Int J Biol Sci 2021 13;17(13):3522-3537. Epub 2021 Aug 13.

Institute of Ultrasound Imaging, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.

Of all pathological types of renal cell cancer (RCC), clear cell renal cell carcinoma (ccRCC) has the highest incidence. Cyclovirobuxine (CVB), a triterpenoid alkaloid isolated from , exhibits antitumour activity against gastric cancer and breast cancer; however, the mechanism by which CVB inhibits ccRCC remains unclear. The aim of our study was to explore the antitumour effects of CVB on ccRCC and to elucidate its exact mechanism. Read More

View Article and Full-Text PDF

LncRNA SNHG17 promotes tumor progression and predicts poor survival in human renal cell carcinoma via sponging miR-328-3p.

Aging (Albany NY) 2021 Sep 8;13(undefined). Epub 2021 Sep 8.

Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, He'nan Province, China.

Accumulating data shows that dysregulation of long non-coding RNAs (lncRNAs) are involved in human tumors' occurrence and progression. Small nucleolar RNA host genes (SNHGs) are recently revealed to play a carcinogenic role in various human neoplasms. However, the functions and underlying mechanisms of lncRNA SNHG17 in renal cell carcinoma (RCC) are still elusive. Read More

View Article and Full-Text PDF
September 2021

Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma.

Jpn J Clin Oncol 2021 Sep 8. Epub 2021 Sep 8.

Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.

Objectives: To investigate the prognostic impact of tumor burden in patients receiving nivolumab plus ipilimumab as first-line therapy for previously untreated metastatic renal cell carcinoma (mRCC).

Methods: We retrospectively evaluated 62 patients with IMDC intermediate- or poor-risk mRCC, treated with nivolumab plus ipilimumab as first-line therapy at five affiliated institutions. Tumor burden was defined as the sum of diameters of baseline targeted lesions according to the RECIST version. Read More

View Article and Full-Text PDF
September 2021

Radiology- and gene-based risk stratification in small renal cell carcinoma: A preliminary study.

PLoS One 2021 7;16(9):e0256471. Epub 2021 Sep 7.

Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Purpose: Most small renal cell carcinomas (small RCCs) will remain indolent after detection, but some stage I RCCs still metastasize. There are no risk-stratification imaging factors that could be used to identify poor-prognosis patients based on genomic profiling. Here, we evaluated the relationships between imaging parameters and RNA expressions in small RCC and attempted to identify imaging factors that could be used as effective biomarkers. Read More

View Article and Full-Text PDF
September 2021

Regulation of the PTEN/PI3K/AKT pathway in RCC using the active compounds of natural products .

Mol Med Rep 2021 Nov 7;24(5). Epub 2021 Sep 7.

Urology and Nephrology Institute of Ningbo University, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, P.R. China.

Since Professor Tu Youyou won the 2015 Nobel Prize in Physiology and Medicine for the discovery of artemisinin, which is used to treat malaria, increased attention has been paid to the extracts obtained from plants, in order to analyze their biological activities, particularly with regard to their antitumor activity. Therefore, the present study explored the biochemical properties of seven natural plant extracts on renal cell carcinoma (RCC). 786‑O and OS‑RC‑2 cells were cultured and treated with different concentrations of the extracts. Read More

View Article and Full-Text PDF
November 2021

Circular RNAs and their role in renal cell carcinoma: a current perspective.

Cancer Cell Int 2021 Sep 6;21(1):469. Epub 2021 Sep 6.

Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, People's Republic of China.

Circular RNAs (circRNAs) are a new class of long non-coding RNAs, that results from a special type of alternative splicing referred to as back-splicing. They are widely distributed in eukaryotic cells and demonstrate tissue-specific expression patterns in humans. CircRNAs actively participate in various important biological activities like gene transcription, pre-mRNA splicing, translation, sponging miRNA and proteins, etc. Read More

View Article and Full-Text PDF
September 2021

Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma.

Acta Dermatovenerol Croat 2021 Apr;291(1):54-55

Inigo Navarro-Fernandez, MD, Calle Mirador del Candado, , 1 29018 Malaga (Spain),

Dear Editor, Nivolumab is a fully human monoclonal antibody that targets the programmed cell death 1 (PD-1) immune checkpoint. It has been approved for its use in several types of advanced solid tumors, including melanoma, lung cancer, and renal cell carcinoma (RCC). The inhibition of PD-1 leads to an enhanced adaptive immune response against tumor cells through the activation of T-cells. Read More

View Article and Full-Text PDF

THSD7A expression: a novel immunohistochemical determinant in predicting overall survival of metastatic renal cell carcinoma treated with targeted therapy.

Ir J Med Sci 2021 Sep 1. Epub 2021 Sep 1.

Department of Preventive Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.

Background: The association of thrombospondin type 1 domain-containing 7A (THSD7A) expression, a novel angiogenesis-related marker, with survival outcomes of tumors including renal cell carcinoma (RCC) remains to be clarified. Therefore, we investigated the impact of THSD7A on outcomes of metastatic RCC (mRCC) patients treated with targeted therapy.

Methods: A total of 86 mRCC patients were included. Read More

View Article and Full-Text PDF
September 2021

UBA2 promotes the progression of renal cell carcinoma by suppressing the p53 signaling.

Ir J Med Sci 2021 Aug 31. Epub 2021 Aug 31.

Department of Urology, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, 121001, People's Republic of China.

Background: Renal cell carcinoma or RCC is a type of malignancy commonly occurred in the human kidney especially in the adults. The pathogenesis of RCC involves the complex networking of multiple signaling pathways, and the underlying molecular mechanisms remain largely unclear.

Objectives: This study aimed to elucidate the regulatory functions of UBA2 and explore its potential downstream molecules during the tumor progression in RCC. Read More

View Article and Full-Text PDF

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma.

Eur Urol Open Sci 2021 Sep 15;31:1-9. Epub 2021 Jul 15.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Background: The lenvatinib (LEN) plus everolimus (EVE) combination demonstrated improved progression-free survival over everolimus alone in a phase 2 trial (Study-205).

Objective: To compare quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) between LEN + EVE and EVE alone among patients with advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapy.

Design Setting And Participants: This was a post hoc analysis of Study-205. Read More

View Article and Full-Text PDF
September 2021

Local recurrence and other oncologic outcomes after percutaneous image-guided tumor ablations on stageT1b renal cell carcinoma: a systematic review and network meta-analysis.

Int J Hyperthermia 2021 ;38(1):1295-1303

Service d'imagerie diagnostique et thérapeutique de l'adulte, Hôpital Pellegrin, Place Amélie-Raba-Léon, Bordeaux, France.

Objective: A systematic review of clinical trials on thermal ablation of T1b RCC was conducted to assess oncologic outcomes of those procedures. The primary endpoint was the rate of local recurrence. Secondary endpoints included technical efficacy, progression to metastatic disease, cancer-specific mortality, complications and renal function decrease. Read More

View Article and Full-Text PDF
September 2021

Sunitinib increases the cancer stem cells and vasculogenic mimicry formation via modulating the lncRNA-ECVSR/ERβ/Hif2-α signaling.

Cancer Lett 2021 Aug 27. Epub 2021 Aug 27.

Departments of Urology, Pathology and the Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, 14642, USA. Electronic address:

Sunitinib is the first-line drug for treating renal cell carcinoma (RCC), and it functions mainly through inhibition of tumor angiogenesis. However, the patients may become insensitive or develop resistance toward sunitinib treatment, but the underlying mechanisms have not yet been fully elucidated. Herein, it was found that sunitinib could have adverse effects of promoting RCC progression by increasing vascular mimicry (VM) formation of RCC cells. Read More

View Article and Full-Text PDF

A Systematic Review and Meta-Analysis of Dual Therapy in Patients with Advanced Renal Cell Carcinoma of Favourable Risk.

Urology 2021 Aug 27. Epub 2021 Aug 27.

Division of Medical Oncology, Department of Oncology, Queen's University, Kingston Ontario Canada. Electronic address:

Objective: To define the impact of first-line dual therapy involving immune checkpoint inhibitors (ICI) on survival outcomes in patients with advanced renal cell carcinoma (aRCC) of International Metastatic RCC Database Consortium (IMDC) favourable-risk.

Materials And Methods: Systematic review of Medline, EMBASE, and Cochrane Central Register of Controlled trials were conducted to select all phase II/III RCTs involving first-line, palliative-intent dual therapy in aRCC patients of favourable-risk. Inverse-variance with random-effects model was used for meta-analysis. Read More

View Article and Full-Text PDF

Prognostic significance and tumor-immune infiltration of mTOR in clear cell renal cell carcinoma.

PeerJ 2021 17;9:e11901. Epub 2021 Aug 17.

Department of Pediatric Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Jinan, Shandong, China.

Mammalian target of rapamycin (mTOR), a serine/threonine kinase involved in cell proliferation, survival, metabolism and immunity, was reportedly activated in various cancers. However, the clinical role of mTOR in renal cell carcinoma (RCC) is controversial. Here we detected the expression and prognosis of total mTOR and phosphorylated mTOR (p-mTOR) in clear cell RCC (ccRCC) patients, and explored the interactions between mTOR and immune infiltrates in ccRCC. Read More

View Article and Full-Text PDF

An international pooled analysis of SBRT outcomes to oligometastatic spine and non-spine bone metastases.

Radiother Oncol 2021 Aug 26. Epub 2021 Aug 26.

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address:

Purpose: There is a paucity of data on SBRT to non-spine bone (NSB) lesions compared to spine metastases. We report local recurrence (LR), widespread progression (WSP), and overall survival (OS) for oligometastatic patients treated to bone lesions with SBRT and investigate the hypothesis that outcomes are different between patients with spine and non-spine bone oligometastatic disease.

Methods: Patients with oligometastatic disease (≤5 cumulative extracranial metastases) treated with bone SBRT at 6 international institutions from 2007 - 2016 were reviewed. Read More

View Article and Full-Text PDF

promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma.

J Immunother Cancer 2021 Aug;9(8)

Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany

Background: In metastatic clear cell renal cell carcinoma (ccRCC), different combination therapies, each including anti-PD-1 immune checkpoint blockade (ICB), are applied as first-line treatment. Robust predictive biomarkers for rational upfront therapy decisions are lacking, although they are urgently needed. Recently, we showed that promoter methylation predicts response to ICB in melanoma. Read More

View Article and Full-Text PDF

Low Preoperative Mean Platelet Volume/Platelet Count Ratio Indicates Worse Prognosis in Non-Metastatic Renal Cell Carcinoma.

J Clin Med 2021 Aug 19;10(16). Epub 2021 Aug 19.

Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.

Objectives: Multiple blood parameters are used to determine the prognosis of renal cell carcinoma (RCC). Mean platelet volume/platelet count (MPV/PC) ratio is related to disease progression in various cancers. Our study tried to evaluate the prognostic value of the MPV/PC ratio in RCC patients who underwent surgery. Read More

View Article and Full-Text PDF

The Roadmap of RANKL/RANK Pathway in Cancer.

Cells 2021 Aug 4;10(8). Epub 2021 Aug 4.

Luis Costa Laboratory, Instituto de Medicina Molecular-João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisboa, Portugal.

The receptor activator of the nuclear factor-κB ligand (RANKL)/RANK signaling pathway was identified in the late 1990s and is the key mediator of bone remodeling. Targeting RANKL with the antibody denosumab is part of the standard of care for bone loss diseases, including bone metastases (BM). Over the last decade, evidence has implicated RANKL/RANK pathway in hormone and HER2-driven breast carcinogenesis and in the acquisition of molecular and phenotypic traits associated with breast cancer (BCa) aggressiveness and poor prognosis. Read More

View Article and Full-Text PDF

Urine LOX-1 and Volatilome as Promising Tools towards the Early Detection of Renal Cancer.

Cancers (Basel) 2021 Aug 21;13(16). Epub 2021 Aug 21.

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

Renal cell carcinoma (RCC) represents around 3% of all cancers, within which clear cell RCC (ccRCC) are the most common type (70-75%). The RCC disease regularly progresses asymptomatically and upon presentation is recurrently metastatic, therefore, an early method of detection is necessary. The identification of one or more specific biomarkers measurable in biofluids (i. Read More

View Article and Full-Text PDF

Expression of TXNIP is associated with angiogenesis and postoperative relapse of conventional renal cell carcinoma.

Sci Rep 2021 Aug 25;11(1):17200. Epub 2021 Aug 25.

Department of Urology, Medical School, University of Pecs, Pecs, Hungary.

One of the common mediator of tumour progression is the oxidative stress induced by inflammatory tumour microenvironment (TME). Activated fibroblasts, local and immune cells produce reactive oxygen species (ROS) supporting tumour cell proliferation and pave the way for metastatic tumour growth. TXNIP regulates ROS generation by inhibiting the antioxidative function of thioredoxin (TXN). Read More

View Article and Full-Text PDF

Pseudogene HSPB1P1 contributes to renal cell carcinoma proliferation and metastasis by targeting miR-296-5p to regulate HMGA1 expression.

Cell Biol Int 2021 Aug 25. Epub 2021 Aug 25.

Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

With the aid of next-generation sequencing technology, pseudogenes have been widely recognized as functional regulators in the development and progression of certain diseases, especially cancer. Our present study aimed to investigate the functions and molecular mechanisms of HSPB1-associated protein 1 pseudogene 1 (HSPB1P1) in renal cell carcinoma (RCC). HSPB1P1 expression at the mRNA levels was determined by quantitative real-time polymerase chain reaction, and its clinical significance was assessed. Read More

View Article and Full-Text PDF

First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.

Eur J Cancer 2021 Aug 18;156:35-45. Epub 2021 Aug 18.

Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. Electronic address:

Background: The EXTREME regimen (chemotherapy [CT; cisplatin/carboplatin and 5-fluorouracil]) plus cetuximab is a standard-of-care first-line (1L) treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), as supported by international guidelines. The phase III CHANGE-2 trial assessed the efficacy and safety of a modified CT regimen (with a reduced dose of both components) and cetuximab versus CT for the 1L treatment of Chinese patients with R/M SCCHN.

Methods: Patients were randomised to receive up to six cycles of CT plus cetuximab followed by cetuximab maintenance until progressive disease or CT alone. Read More

View Article and Full-Text PDF